Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 9/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SIK1 | P57059 | 6/20 | 0.35 |
| ▸ | SIK2 | Q9H0K1 | 6/20 | 0.35 |
| ▸ | SIK3 | Q9Y2K2 | 6/20 | 0.35 |
| ▸ | ABL1 | P00519 | 5/20 | 0.35 |
| ▸ | CSF1R | P07333 | 5/20 | 0.35 |
| ▸ | LYN | P07948 | 5/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 5/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.35 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.35 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19259781 | 0.92 | LOXL2 (0.49) | LOXL2LOXL3KAT5 | |
| SCHEMBL20983544 | 0.89 | LOXL2 (0.47) | LOXL2 | |
| SCHEMBL29971483 | 0.89 | LOXL2 (0.46) | LOXL2GAASIK1SIK2SIK3 | |
| SCHEMBL19274619 | 0.89 | LOXL2 (0.46) | LOXL2GAASIK1SIK2SIK3 | |
| SCHEMBL19259611 | 0.86 | LOXL2 (0.50) | LOXL2SIK1SIK2SIK3ABL1 | |
| SCHEMBL19259729 | 0.84 | LOXL2 (0.49) | LOXL2LOXL3KDM4EALDH1A1HPGD | |
| SCHEMBL28639354 | 0.84 | LOXL2 (0.51) | LOXL2SIK1SIK2SIK3ABL1 | |
| SCHEMBL21016676 | 0.81 | LOXL2 (0.46) | LOXL2LOXL3DYRK1A | |
| SCHEMBL19259834 | 0.81 | LOXL2 (0.74) | LOXL2 | |
| SCHEMBL19259684 | 0.79 | LOXL2 (0.34) | LOXL2LOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416956-B1 | METHYLAMINE DERIVATIVES AS LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-20 | — | — | US | disclosed |
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-05-23 | — | — | US | disclosed |
| EP-3416956-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | LOXL2 3/4885GAA 1993/4885SIK1 2951/4885 |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | LOXL2 3/4885GAA 1993/4885SIK1 2951/4885 |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | LOXL2 3/4885GAA 1993/4885SIK1 2951/4885 |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | LOXL2 3/4885GAA 1993/4885SIK1 2951/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | LOXL2 3/4885GAA 1993/4885SIK1 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.